MS PHARMA VENTURES HOLDING W.L.L announces a license, supply and distribution agreement with SINOVAC BIOTECH CO., LTD. for Sinovac’s WHO PQ approved Hepatitis A vaccine HEALIVE® for the Jordanian market.
Hepatitis A vaccine demand has recently been reintroduced in the National Vaccination Program in Jordan. HEALIVE® vaccine, manufactured by Sinovac, has passed the assessment under WHO Prequalification procedures in 2017.
This step comes at the heart of MS Pharma’s crucial strategy to supply the pharmaceutical market with outstanding products covering unmet needs in specialized and advanced therapeutic areas.
Dr. Essam Farouk – MS Pharma’ CEO stated in this occasion “our commitment is to serve our communities and improve the standard of health in our local market and other countries of presence, by partnering with global innovative external pharmaceutical companies”.
Sinovac management team as well assured the importance on such step that helps in reaching more patients with new medications that will help improve the community’s health in the Middle East and Africa by collaborating with well-established regional pharmaceutical company.
About Sinovac
Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases.
About MS Pharma
MS Pharma is a leading pharmaceutical company and strategic partner in the Middle East, Africa, Turkey, and Europe. The company is based in Jordan, has several plants in Jordan, Algeria, Greece, Saudi Arabia, and Turkey, and exports to over 60 countries worldwide. The company has the capability to manufacture branded generics and oncology products in different dosage forms including oral, topical and injectable forms.
© Press Release 2019Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.
The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.
To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.
